Filtered By:
Specialty: Cardiology
Nutrition: Omega 3
This page shows you your search results in order of date.
Order by Relevance | Date
Total 31 results found since Jan 2013.
The Potential Cardiometabolic Effects of Long-Chain Omega-3 Polyunsaturated Fatty Acids: Recent Updates and Controversies
Adv Nutr. 2023 Apr 7:S2161-8313(23)00283-1. doi: 10.1016/j.advnut.2023.03.014. Online ahead of print.ABSTRACTVarious health-related effects of long-chain (LC) omega-3 polyunsaturated fatty acids (PUFAs), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have been suggested. LC omega-3 PUFAs reduce triglyceride levels and have anti-inflammatory, immunomodulatory, antiplatelet, and vascular protective effects. Controversially, they might help in restoring glucose homeostasis via the gut microbiota. However, previous studies have not shown the clear benefits of LC omega-3 PUFAs for cardiovascular diseases. REDUCE-IT...
Source: Atherosclerosis - April 9, 2023 Category: Cardiology Authors: Jae Hyun Bae Hyunjung Lim Soo Lim Source Type: research
Efficacy and Safety of Omega-3 Fatty Acids in the Prevention of Cardiovascular Disease: A Systematic Review and Meta-analysis
ConclusionModerate evidence showed that the use of omega-3 fatty acids may reduce the risk of major cardiovascular events, myocardial infarction, and cardiovascular death. Compared to other types of omega-3 fatty acids supplements, we support the use of prescription EPA ethyl ester formulations for the prevention of cardiovascular disease, but the potential risk of atrial fibrillation and bleeding cannot be ignored. It is important to note that omega-3 fatty acids should be applied with caution in patients with previous myocardial infarction, which may increase the risk of stroke. Finally, omega-3 fatty acids are relativel...
Source: Cardiovascular Drugs and Therapy - September 14, 2022 Category: Cardiology Source Type: research
Eicosapentaenoic Acid for Cardiovascular Events Reduction- Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
CONCLUSIONS: Our analyses demonstrate that although EPA supplementation lowers risk of coronary revascularization more than other oils, there may not be a benefit relative to standard of care. Further, EPA reduces the risk of cardiovascular events only in comparison to mineral oil and not when compared with other placebo oils or controls. In contrast, combined EPA+DHA was associated with reduced risk of cardiovascular death compared to controls.PMID:35914996 | DOI:10.1016/j.jjcc.2022.07.008
Source: Journal of Cardiology - August 1, 2022 Category: Cardiology Authors: Yujiro Yokoyama Toshiki Kuno Sae X Morita Leandro Slipczuk Hisato Takagi Alexandros Briasoulis Azeem Latib Sripal Bangalore Sean P Heffron Source Type: research
Omega-3 fatty acids, subclinical atherosclerosis, and cardiovascular events: Implications for primary prevention
CONCLUSIONS: In an ethnically diverse population free of clinical CVD, higher plasma omega-3 fatty acid levels were associated with fewer long-term CVD events. The absolute decrease in CVD events with higher omega-3 fatty acid levels was more apparent at higher CAC scores.PMID:35759823 | DOI:10.1016/j.atherosclerosis.2022.06.1018
Source: Atherosclerosis - June 27, 2022 Category: Cardiology Authors: Abdulhamied Alfaddagh Karan Kapoor Zeina A Dardari Deepak L Bhatt Matthew J Budoff Khurram Nasir Michael Miller Francine K Welty Michael D Miedema Michael D Shapiro Michael Y Tsai Roger S Blumenthal Michael J Blaha Source Type: research
Correspondence on 'Omega-3 supplementation and cardiovascular disease: formulation-based systematic review and meta-analysis with trial sequential analysis' by Rizos et al
In their review and meta-analysis, Rizos et al1 reported that omega-3 supplementation at low and higher dosages showed no or weak associations with cardiovascular disease (CVD) outcomes, respectively. More recent reviews also showed protective activity of omega-3 against CVD outcomes. For instance, omega-3 (2–4 g/day) in patients with high or very high triglyceride (TG) levels decreases significantly high-sensitivity C reactive protein (hsCRP), lipoprotein-associated phospholipase A2 (Lp-PLA2), and oxidised low density lipoprotein (LDL)-cholesterol (oxLDL) levels, and the reduction of hsCRP is enhanced when co-admini...
Source: Heart - March 25, 2022 Category: Cardiology Authors: Kountouras, J., Doulberis, M., Kazakos, E., Tzika, S. K., Vardaka, E., Liatsos, C., Papaefthymiou, A. Tags: Correspondence Source Type: research
Association Between Omega-3 Fatty Acid Treatment and Atrial Fibrillation in Cardiovascular Outcome Trials: A Systematic Review and Meta-Analysis
ConclusionWhile overall AF event rates were low, n-3 FA treatment is associated with increased risk for AF.
Source: Cardiovascular Drugs and Therapy - August 1, 2021 Category: Cardiology Source Type: research
Long-term dietary supplementation with plant-derived omega-3 fatty acid improves outcome in experimental ischemic stroke
Early revascularization -the gold standard therapy for ischemic stroke-is often withheld in the elderly population due to high risk of complications. Thus, safe and effective preventive and therapeutic options are needed. The plant-derived omega-3-fatty-acid alpha-linolenic-acid (ALA) has emerged as a potential cardiovascular-protective agent. As of yet, little is known about its potential therapeutic effects on stroke. We hereby aimed to investigate the impact of a clinically relevant long-term dietary intervention with ALA on stroke outcome.
Source: Atherosclerosis - April 19, 2021 Category: Cardiology Authors: Nicole R. Bonetti, Luca Liberale, Alexander Akhmedov, Lisa Pasterk, Sara Gobbato, Yustina M. Puspitasari, Ana Vukolic, Seyed Soheil Saeedi Saravi, Bernd Coester, Carla Horvath, Elena Osto, Fabrizio Montecucco, Thomas F. L üscher, Jürg H. Beer, Giovanni Source Type: research
